Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
6.60
-0.15 (-2.22%)
Dec 5, 2025, 4:00 PM EST - Market closed
Profound Medical Revenue
Profound Medical had revenue of $5.29M in the quarter ending September 30, 2025, with 86.76% growth. This brings the company's revenue in the last twelve months to $14.30M, up 67.94% year-over-year. In the year 2024, Profound Medical had annual revenue of $10.68M with 48.35% growth.
Revenue (ttm)
$14.30M
Revenue Growth
+67.94%
P/S Ratio
13.82
Revenue / Employee
$100,683
Employees
142
Market Cap
197.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.68M | 3.48M | 48.35% |
| Dec 31, 2023 | 7.20M | 518.00K | 7.75% |
| Dec 31, 2022 | 6.68M | -192.00K | -2.79% |
| Dec 31, 2021 | 6.87M | -431.00K | -5.90% |
| Dec 31, 2020 | 7.30M | 3.13M | 74.99% |
| Dec 31, 2019 | 4.17M | 2.26M | 117.58% |
| Dec 31, 2018 | 1.92M | -1.98M | -50.81% |
| Dec 31, 2017 | 3.90M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PROF News
- 1 day ago - Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation - GlobeNewsWire
- 8 days ago - Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings - GlobeNewsWire
- 18 days ago - Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease - GlobeNewsWire
- 22 days ago - Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Profound Medical Reports Strong Third Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand - GlobeNewsWire
- 25 days ago - Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia - GlobeNewsWire
- 7 weeks ago - Profound Medical to Participate in the Stifel 2025 Healthcare Conference - GlobeNewsWire